Substance / Medication

Carbachol

Overview

Active Ingredient
carbachol
RxNorm CUI
1999

Indications

YUVEZZI™ is indicated for the treatment of presbyopia in adults.

Labeler: Visus Therapeutics, Inc.Updated: 2026-02-19T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

YUVEZZI is contraindicated in patients with known hypersensitivity to the active ingredients or to any of the excipients.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

136 trials linked to this intervention

136
Total Trials
11
Recruiting
53
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Investigation of carbachol and PACAP38 in a human model of migraine.
Schytz Henrik Winther · Dan Med Bull · 2010
PMID: 21122466RCT
Carbachol induces headache, but not migraine-like attacks, in patients with migraine without aura.
Schytz H W, Wienecke T, Olesen J et al. · Cephalalgia · 2010
PMID: 19614687RCT
The cholinomimetic agent carbachol induces headache in healthy subjects.
Schytz H W, Wienecke T, Oturai P S et al. · Cephalalgia · 2009
PMID: 19143771RCT
Effects of Capsaicin and Carbachol on Secretion From Transplanted Submandibular Glands and Prevention of Duct Obstruction.
Su Jia-Zeng, Liu Xiao-Jing, Wang Yang et al. · Cornea · 2016
PMID: 26807899Observational
Effect of intracameral carbachol given during cataract surgery on macular thickness.
Demir Mehmet, Oba Ersin, Dirim Burcu et al. · Int Ophthalmol · 2012
PMID: 22576110Observational
Carbachol alleviates rat cytokine release and organ dysfunction induced by lipopolysaccharide.
Zhou Guoyong, Hu Sen, Lv Yi et al. · J Trauma · 2011
PMID: 20805763Observational
Modeling carbachol-induced hippocampal network synchronization using hidden Markov models.
Dragomir Andrei, Akay Yasemin M, Akay Metin · J Neural Eng · 2010
PMID: 20841638Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Carbachol (substance)
SNOMED CT
387183001
UMLS CUI
C0006945
RxNorm CUI
1999
Labeler
Visus Therapeutics, Inc.

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

1
Conditions
1
Biomarkers
1
Specialists
0
Symptoms
136
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.